These findings suggest that components of the FXR signaling pathway, including gut bacteria that convert primary bile acids into secondary bile acids, are potential therapeutic targets for NAFLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.